Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Sep 3;332(9):730-737.
doi: 10.1001/jama.2024.11437.

Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions

Affiliations
Comparative Study

Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions

Erika Y Lee et al. JAMA. .

Abstract

Importance: Serious cutaneous adverse drug reactions (cADRs) are potentially life-threatening drug hypersensitivity reactions involving the skin and internal organs. Antibiotics are a recognized cause of these reactions, but no studies have compared relative risks across antibiotic classes.

Objectives: To explore the risk of serious cADRs associated with commonly prescribed oral antibiotics, and to characterize outcomes of patients hospitalized for them.

Design, setting, and participants: Nested case-control study using population-based linked administrative datasets among adults aged 66 years or older who received at least 1 oral antibiotic between 2002 and 2022 in Ontario, Canada. Cases were those who had an emergency department (ED) visit or hospitalization for serious cADRs within 60 days of the prescription, and each case was matched with up to 4 controls who did not.

Exposure: Various classes of oral antibiotics.

Main outcomes and measures: Conditional logistic regression estimate of the association between different classes of oral antibiotics and serious cADRs, using macrolides as the reference group.

Results: During the 20-year study period, we identified 21 758 older adults (median age, 75 years; 64.1% female) who had an ED visit or hospitalization for serious cADRs following antibiotic therapy and 87 025 matched controls who did not. In the primary analysis, sulfonamide antibiotics (adjusted odds ratio [aOR], 2.9; 95% CI, 2.7-3.1) and cephalosporins (aOR, 2.6; 95% CI, 2.5-2.8) were most strongly associated with serious cADRs relative to macrolides. Additional associations were evident with nitrofurantoin (aOR, 2.2; 95% CI, 2.1-2.4), penicillins (aOR, 1.4; 95% CI, 1.3-1.5), and fluoroquinolones (aOR, 1.3; 95% CI, 1.2-1.4). The crude rate of ED visits or hospitalization for cADRs was highest for cephalosporins (4.92 per 1000 prescriptions; 95% CI, 4.86-4.99) and sulfonamide antibiotics (3.22 per 1000 prescriptions; 95% CI, 3.15-3.28). Among the 2852 case patients hospitalized for cADRs, the median length of stay was 6 days (IQR, 3-13 days), 9.6% required transfer to a critical care unit, and 5.3% died in the hospital.

Conclusion and relevance: Commonly prescribed oral antibiotics are associated with an increased risk of serious cADRs compared with macrolides, with sulfonamides and cephalosporins carrying the highest risk. Prescribers should preferentially use lower-risk antibiotics when clinically appropriate.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Drucker reported receiving compensation from the British Journal of Dermatology as reviewer and section editor, the American Academy of Dermatology as guidelines writer, Canadian Dermatology Today as manuscript writer, and the National Eczema Association and the Canadian Agency for Drugs and Technologies in Health as consultant; he reported receiving research grants to his institution from the National Eczema Association, Eczema Society of Canada, Canadian Dermatology Foundation, Canadian Institutes for Health Research, US National Institutes of Health, and Physicians Services Incorporated Foundation. Dr Piguet reported receiving grants from AbbVie, Bausch Health, Celgene, Lilly, Incyte, Janssen, LEO Pharma, L’Oréal, Novartis, Organon, Pfizer, Sandoz, Amgen, and Boehringer Ingelheim; receiving payment or honoraria for speaking from Sanofi China; participating on advisory boards for LEO Pharma, Novartis, Sanofi, and Union Therapeutics; and receiving equipment donation from L’Oréal. No other disclosures were reported.

Figures

Figure.
Figure.. Comparative Risks of Serious cADRs by Antibiotic Class Using a 60-Day Latency Period (Primary Analysis) and a 30-Day Latency Period (Sensitivity Analysis)
To explore the risks of serious cutaneous adverse drug reactions (cADRs) by antibiotic class, we used a maximum 60-day latency period between antibiotic initiation and the index date in the primary analysis and a maximum 30-day latency period in the sensitivity analysis. Odds ratios are adjusted for malignancy, chronic kidney disease, chronic liver disease, HIV infection, location of residence, long-term care facility, income quintile, and numbers of prescribed drugs, emergency department visits, hospitalizations, and outpatient physician visits in the preceding year.

References

    1. Mockenhaupt M, Viboud C, Dunant A, et al. . Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs: the EuroSCAR-study. J Invest Dermatol. 2008;128(1):35-44. doi:10.1038/sj.jid.5701033 - DOI - PubMed
    1. Finkelstein Y, Macdonald EM, Li P, Hutson JR, Juurlink DN. Recurrence and mortality following severe cutaneous adverse reactions. JAMA. 2014;311(21):2231-2232. doi:10.1001/jama.2014.839 - DOI - PubMed
    1. Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390(10106):1996-2011. doi:10.1016/S0140-6736(16)30378-6 - DOI - PubMed
    1. Frey N, Jossi J, Bodmer M, et al. . The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 2017;137(6):1240-1247. doi:10.1016/j.jid.2017.01.031 - DOI - PubMed
    1. Zhang C, Van DN, Hieu C, Craig T. Drug-induced severe cutaneous adverse reactions: determine the cause and prevention. Ann Allergy Asthma Immunol. 2019;123(5):483-487. doi:10.1016/j.anai.2019.08.004 - DOI - PubMed

Publication types

MeSH terms